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Editorial on the Research Topic
From Biology to Clinical Management: An Update on Aortic Valve Disease
Calcific aortic stenosis (AS) is the most frequent valvular heart disease in Western countries,
affecting up to 13% of individuals over 75 years (1, 2). The disease is associated with considerable
morbidity and mortality. Major risk factors include older age, congenital anomalies of the aortic
valve (bicuspid valve), male gender, hypertension, dyslipidaemia, smoking, and diabetes (3).
The disease is characterized by fibro-calcification of aortic valve cusps and concomitant left
ventricular (LV) remodeling due to chronic pressure overload, which can evolve into overt heart
failure. AS progresses very slowly until the onset of symptoms (angina, dyspnae, syncope). A
large majority of patients remain asymptomatic for a long period, though at increased risk for
untoward events (death, heart failure, symptomatic deterioration, LV dysfunction). Development
of symptoms is a class I indication for aortic valve replacement (AVR). Today, about 300,000
AVR are performed annually worldwide, either via surgery (SAVR) or transcatheter implantation
(TAVI). AVR is indeed the only treatment shown to improve survival. There is no pharmacological
treatment to prevent or slow disease progression.
The present research topic provides a comprehensive overview of AS clinical management with
a special focus on valve prostheses, imaging and blood biomarkers as well as on recent advances on
pathophysiology and valve biology.
Regarding valve prostheses, the ideal prosthesis either mechanical or biological still do not
exist. Current prosthesis can cause complications, which necessitate reoperation or lead to death
in 50–60% of patients within 10 years post-implantation. In this research topic, Musumeci et al.
reviewed the different types of currently available prosthetic aortic valves and their limitations.
It appears that thrombosis, infection, bioprosthesis calcification, and degeneration remain major
issues, which could be addressed through innovative new generation prostheses.
Rachwan et al. report on a patient who presented with a thrombus on a bicuspid aortic valve in
the setting of antiphospholipid syndrome (APLS). APLS is a systemic autoimmune disease defined
by thrombotic events in patients persistently positive for antiphospholipid antibodies (aPL). In this
case report, 4-months moderate-intensity anticoagulation efficiently eliminated the aortic valve
thrombus. However, due to the rarity of this condition, whether conservative anticoagulation or
AVR should be recommended remains to be determined. More generally, there is currently no
clear recommendation on the choice of antithrombotic regimen for AS patients (4, 5).
Another major challenge in the clinical management of AS is deciding on the correct timing of
AVR (6).
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Regarding clinical imaging, echocardiography is central to
the diagnosis and risk stratification of patients with aortic
stenosis and regurgitation. However, the technique has certain
limitations, and aortic valve imagingmay benefit from alternative
and complimentary multimodality imaging. In the present
topic, Nchimi et al. performed a systematic review and meta-
analysis in order to evaluate the role of imaging biomarkers in
predicting AS progression to clinical symptoms and mortality.
Eight studies regrouping 1,639 patients were included in the
analysis. This study showed significant associations of computed
tomography aortic valve calcification (AVC) and myocardial
fibrosis, measured by cardiac magnetic resonance (CMR), with
clinical outcomes. The findings on AVC are in line with a
recent study showing that sex-specific AVC thresholds accurately
identify severe AS and predicts AVR and death (7). Late
enhancement gadolinium fibrosis was significantly associated
with cardiac mortality, which is in agreement with another recent
meta-analysis indicating that LV fibrosis can also have prognostic
value after AVR (8). Hence, the prognostic efficacy of these
imaging biomarkers for patient management as compared to the
current approach that relies mainly on clinical performance need
to be tested in large randomized studies.
In addition to clinical imaging, several studies strongly suggest
that circulating biomarkers could help for AS patient risk
stratification (9). In this research topic, Oury et al. reviewed
the role of circulating biomarkers in patients undergoing TAVI.
Despite the fact that TAVI offers a marked change in life
expectancy and quality of life of high-risk elderly patients,
(10) early and late mortality after TAVI still remains relatively
high (11–13). Studies indicate that implementing biomarkers of
myocardial injury, cardiacmechanical stretch, inflammation, and
of hemostasis imbalance in clinical practice might help reducing
TAVI-associated complications and mortality. However, the role
of these biomarkers has yet to be confirmed in large randomized
studies.
Nevertheless, the identification of novel biomarkers will
necessitate a better understanding of aortic valve biology and
mechanisms of disease. The review by Hulin et al. draws
a summary of current knowledge on pathogenic pathways
and their potential role as novel therapeutic targets. Heart
valve homeostasis is tightly controlled by valve interstitial cells
(VICs) embedded in extracellular matrix, valve endothelial
cells (VECs) covering the leaflet, and circulating and resident
immune cells. AS is now considered as an active multi-step
process. Early steps of lesion development would occur through
accumulation of lipids and free cholesterol within the fibrosa,
followed by infiltration of inflammatory cells, e.g., macrophages
and T lymphocytes. VICs then enter an osteogenic program,
initiating calcium nodule formation, and valve calcification
(2). All these events likely involve mechanical stress and
strain, and a major role for valve lining endothelial cells.
However, how these complex cellular interplay contributes to
AS remains unknown. Furthermore, thorough knowledge of
the heterogeneity and function of valve cell subtypes, over
the course of the disease, may provide useful informations
to develop targeting strategies of diseased cells. In this sense,
transcriptional profiling studies during valve development could
help to better define valve tissue composition and homeostatic
biological pathways. In this research topic, Nordquist et al.
compared mRNA expression in postnatal and adult valve tissues.
This study nicely unveiled multiple conceivable processes that
contribute to postnatal valve maturation and maintenance that
may pave the way for elucidating mechanisms underlying valve
defects.
Thus, this research topic highlights important unmet medical
needs in AS. More basic and translational research is definitely
required to clarify disease mechanisms, uncover new multi-
biomarker-based diagnostic and prognostic tools, and develop
more biocompatible and durable prostheses with the goal of
improving patient outcome.
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